| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Avalo Therapeutics, Inc. (AVTX) has 9 insiders with recent SEC Form 4 filings, including 76 buys and 1 sell. AVTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 275.0K | $4.04M | - | |
| Other | 47.8K | $702.7K | -679 | |
| CFO | 19.1K | $281.0K | - | |
| Other | 3.6K | $53.4K | - | |
| Dir | 3.2K | $46.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 27, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 20,400 | $4.64 | $94,628.59 | - | |
| Aug 17, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 1,000,000 | $3.91 | $3,910,000.00 | +1.9% | |
| Aug 13, 2018 | Jones Randal | 10% Owner | Sale+OE | 1,270 | $3.98 | $5,054.60 | -100% | |
| Jul 31, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 2,855 | $4.25 | $12,134.32 | - | |
| Jul 27, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 28,926 | $4.41 | $127,576.76 | - | |
| Jul 18, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 30,019 | $4.28 | $128,405.07 | - | |
| Jul 2, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 18,200 | $4.11 | $74,757.78 | - | |
| May 23, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 50,000 | $3.78 | $189,174.63 | - | |
| May 18, 2018 | Greenleaf Peter49 | Chief Executive Officer | Buy | 12,500 | $3.98 | $49,750.00 | +3.1% | |
| May 17, 2018 | Armistice Capital, LLC56 | Director, 10% Owner | Buy | 130,000 | $3.60 | $467,633.87 | - |